Likely Flaws Uncovered for LM-Method for Lyme Disease Detection
|
By LabMedica International staff writers Posted on 12 Jul 2016 |

Image: An adult deer tick Ixodes scapularis. Lyme disease is caused by Borrelia bacteria and transmitted to humans upon the bite of infected ticks of the genus Ixodes (Photo courtesy of Scott Bauer, Agricultural Research Service of USDA / Wikimedia).
According to a new study, the recently developed modified microscopy technique “LM-method” of examining blood samples to help diagnose Lyme disease (and babesiosis) – is unable to distinguish infected patients from healthy controls, yielding many false-positive results.
While most people who contract Lyme disease recover quickly after antibiotic treatment, up to 20% of patients report persistent symptoms years after being told standard tests are negative for the disease. Interest in new diagnostic tests is therefore high.
The tick vector Ixodidae transmits Borrelia (bacterial causative agent of Lyme disease) as well as Babesia (parasitic protozoan causative agent of babesiosis). The new research follows up on a previous study suggesting that LM-method could detect active cases of disease caused by Borrelia and/or Babesia in just 1-2 days. Considerable publicity, and thereby patient demand, for this test in Norway continued despite that earlier studies did not include a control group and methods were not validated and ready for use in patients.
To investigate the reliability of the new test, Dr Audun Aase, from the Norwegian Institute of Public Health (Oslo, Norway), and colleagues collected blood samples from people who had been suffering from Lyme disease-like symptoms for several years and previously tested positive for Borrelia and/or Babesia infection using LM-method (21 people), and from healthy controls with no known history of tick bites (41 people). The samples were then masked and analyzed in independent laboratories using a range of diagnostic tests including the LM-method, conventional microscopy, genetic fingerprint testing (PCR), and serology.
The study indicated that LM-method results in high numbers of false positives: 14 (66%) patient-group samples and 35 (85%) control-group samples were judged positive for Borrelia and/or Babesia. However, only 1 sample (5%) of the patient-group and 8 samples (20%) of the control-group tested positive for Borrelia DNA by PCR. None of the samples were positive for Babesia DNA, and conventional microscopy did not identify Babesia in any of the samples. In conclusion, the structures interpreted as Borrelia and Babesia using LM-method could not be verified by PCR and the LM-method was thus falsified.
In an accompanying editorial commentary, Dr Ram B. Dessau, infectious diseases expert and senior consultant at Slagelse Hospital (Slagelse, Denmark), wrote: “I hope the study serves as a warning against non-validated microscopic procedures and helps prevent mismanagement of patients with chronic complaints, who are lured to seek improper diagnosis in the future.”
The study, by Aase A et al, was published online February 2016 in the journal Infectious Diseases.
Related Links:
Norwegian Institute of Public Health
While most people who contract Lyme disease recover quickly after antibiotic treatment, up to 20% of patients report persistent symptoms years after being told standard tests are negative for the disease. Interest in new diagnostic tests is therefore high.
The tick vector Ixodidae transmits Borrelia (bacterial causative agent of Lyme disease) as well as Babesia (parasitic protozoan causative agent of babesiosis). The new research follows up on a previous study suggesting that LM-method could detect active cases of disease caused by Borrelia and/or Babesia in just 1-2 days. Considerable publicity, and thereby patient demand, for this test in Norway continued despite that earlier studies did not include a control group and methods were not validated and ready for use in patients.
To investigate the reliability of the new test, Dr Audun Aase, from the Norwegian Institute of Public Health (Oslo, Norway), and colleagues collected blood samples from people who had been suffering from Lyme disease-like symptoms for several years and previously tested positive for Borrelia and/or Babesia infection using LM-method (21 people), and from healthy controls with no known history of tick bites (41 people). The samples were then masked and analyzed in independent laboratories using a range of diagnostic tests including the LM-method, conventional microscopy, genetic fingerprint testing (PCR), and serology.
The study indicated that LM-method results in high numbers of false positives: 14 (66%) patient-group samples and 35 (85%) control-group samples were judged positive for Borrelia and/or Babesia. However, only 1 sample (5%) of the patient-group and 8 samples (20%) of the control-group tested positive for Borrelia DNA by PCR. None of the samples were positive for Babesia DNA, and conventional microscopy did not identify Babesia in any of the samples. In conclusion, the structures interpreted as Borrelia and Babesia using LM-method could not be verified by PCR and the LM-method was thus falsified.
In an accompanying editorial commentary, Dr Ram B. Dessau, infectious diseases expert and senior consultant at Slagelse Hospital (Slagelse, Denmark), wrote: “I hope the study serves as a warning against non-validated microscopic procedures and helps prevent mismanagement of patients with chronic complaints, who are lured to seek improper diagnosis in the future.”
The study, by Aase A et al, was published online February 2016 in the journal Infectious Diseases.
Related Links:
Norwegian Institute of Public Health
Latest Microbiology News
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
- New Diagnostic Method Confirms Sepsis Infections Earlier
- New Markers Could Predict Risk of Severe Chlamydia Infection
- Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
- CRISPR-Based Saliva Test Detects Tuberculosis Directly from Sputum
- Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People
- Saliva Test Detects Implant-Related Microbial Risks
- New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance
- Early Detection of Gut Microbiota Metabolite Linked to Atherosclerosis Could Revolutionize Diagnosis
- Viral Load Tests Can Help Predict Mpox Severity
- Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
- Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
Simultaneous Analysis of Three Biomarker Tests Detects Elevated Heart Disease Risk Earlier
Accurately identifying individuals at high risk of heart attack remains a major challenge, especially when traditional indicators like cholesterol and blood pressure appear normal. Elevated levels of three... Read more
New Biomarker Panel to Improve Heart Failure Diagnosis in Women
Heart failure affects millions worldwide, yet many women are still misdiagnosed or diagnosed too late. Although heart failure broadly means the heart cannot pump enough blood to the body’s cells, its two... Read moreHematology
view channel
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read more
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read morePathology
view channel
AI Tool Improves Accuracy of Skin Cancer Detection
Diagnosing melanoma accurately in people with darker skin remains a longstanding challenge. Many existing artificial intelligence (AI) tools detect skin cancer more reliably in lighter skin tones, often... Read more
Highly Sensitive Imaging Technique Detects Myelin Damage
Damage to myelin—the insulating layer that helps brain cells function efficiently—is a hallmark of many neurodegenerative diseases, age-related decline, and traumatic injuries. However, studying this damage... Read moreTechnology
view channel
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read more
AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
Early diagnosis of ovarian cancer remains one of the toughest challenges in women’s health. Traditional tools such as the Risk of Ovarian Malignancy Algorithm (ROMA) can struggle to distinguish between... Read more
Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
Early diagnosis of psychiatric disorders such as depression, schizophrenia, and bipolar disorder remains one of medicine’s most pressing challenges. Current diagnostic methods rely heavily on clinical... Read more
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read moreIndustry
view channel
Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
Co-Diagnostics, Inc. (Salt Lake City, UT, USA) has formed a new artificial intelligence (AI) business unit to integrate the company's existing and planned AI applications into its Co-Dx Primer Ai platform.... Read more








